Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 Aug 3;313(7052):275–283. doi: 10.1136/bmj.313.7052.275

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

M F Drummond 1, T O Jefferson 1
PMCID: PMC2351717  PMID: 8704542

Full text

PDF
275

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M. E., McCall N. T., Gray D. T., Orza M. J., Chalmers T. C. Economic analysis in randomized control trials. Med Care. 1992 Mar;30(3):231–243. doi: 10.1097/00005650-199203000-00005. [DOI] [PubMed] [Google Scholar]
  2. Avorn J. Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. N Engl J Med. 1984 May 17;310(20):1294–1301. doi: 10.1056/NEJM198405173102005. [DOI] [PubMed] [Google Scholar]
  3. Birch S., Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy. 1994 May;28(2):133–141. doi: 10.1016/0168-8510(94)90031-0. [DOI] [PubMed] [Google Scholar]
  4. Briggs A., Sculpher M., Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. doi: 10.1002/hec.4730030206. [DOI] [PubMed] [Google Scholar]
  5. Briggs A., Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ. 1995 Sep-Oct;4(5):355–371. doi: 10.1002/hec.4730040502. [DOI] [PubMed] [Google Scholar]
  6. Cairns J. Discounting and health benefits: another perspective. Health Econ. 1992 Apr;1(1):76–79. doi: 10.1002/hec.4730010111. [DOI] [PubMed] [Google Scholar]
  7. Clemens K., Townsend R., Luscombe F., Mauskopf J., Osterhaus J., Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics. 1995 Aug;8(2):169–174. doi: 10.2165/00019053-199508020-00008. [DOI] [PubMed] [Google Scholar]
  8. Drummond M. F., Bloom B. S., Carrin G., Hillman A. L., Hutchings H. C., Knill-Jones R. P., de Pouvourville G., Torfs K. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992 Fall;8(4):671–682. doi: 10.1017/s0266462300002361. [DOI] [PubMed] [Google Scholar]
  9. Drummond M., Brandt A., Luce B., Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993 Winter;9(1):26–36. doi: 10.1017/s0266462300003007. [DOI] [PubMed] [Google Scholar]
  10. Drummond M., Torrance G., Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993 Jul;37(1):33–40. doi: 10.1016/0277-9536(93)90315-u. [DOI] [PubMed] [Google Scholar]
  11. Egberts J. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation. Biol Neonate. 1992;61 (Suppl 1):59–65. doi: 10.1159/000243846. [DOI] [PubMed] [Google Scholar]
  12. Feeny D., Furlong W., Boyle M., Torrance G. W. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics. 1995 Jun;7(6):490–502. doi: 10.2165/00019053-199507060-00004. [DOI] [PubMed] [Google Scholar]
  13. Fordham R., Field D. J., Hodges S., Normand C., Mason E., Burton P., Yates J., Male S. Cost of neonatal care across a regional health authority. J Public Health Med. 1992 Jun;14(2):127–130. [PubMed] [Google Scholar]
  14. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy. 1992 Jul;21(3):249–279. doi: 10.1016/0168-8510(92)90022-4. [DOI] [PubMed] [Google Scholar]
  15. Jefferson T., Demicheli V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Health Econ. 1995 Sep-Oct;4(5):383–388. doi: 10.1002/hec.4730040504. [DOI] [PubMed] [Google Scholar]
  16. Jefferson T., Demicheli V., Entwistle V. Assessing quality of economic submissions to the BMJ. BMJ. 1995 Aug 5;311(7001):393–394. doi: 10.1136/bmj.311.7001.393c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jefferson T., Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ. 1994 Jan-Feb;3(1):25–37. doi: 10.1002/hec.4730030105. [DOI] [PubMed] [Google Scholar]
  18. Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit analysis. Soc Sci Med. 1995 Aug;41(4):483–489. doi: 10.1016/0277-9536(94)00353-u. [DOI] [PubMed] [Google Scholar]
  19. Kassirer J. P., Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994 Sep 8;331(10):669–670. doi: 10.1056/NEJM199409083311009. [DOI] [PubMed] [Google Scholar]
  20. Koopmanschap M. A., Rutten F. F., van Ineveld B. M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995 Jun;14(2):171–189. doi: 10.1016/0167-6296(94)00044-5. [DOI] [PubMed] [Google Scholar]
  21. Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989 Apr-Jun;9(2):142–149. doi: 10.1177/0272989X8900900209. [DOI] [PubMed] [Google Scholar]
  22. Mugford M., Kingston J., Chalmers I. Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources. BMJ. 1989 Oct 21;299(6706):1003–1006. doi: 10.1136/bmj.299.6706.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. O'Brien B. J., Drummond M. F., Labelle R. J., Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994 Feb;32(2):150–163. doi: 10.1097/00005650-199402000-00006. [DOI] [PubMed] [Google Scholar]
  24. Oster G., Epstein A. M. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA. 1987 Nov 6;258(17):2381–2387. [PubMed] [Google Scholar]
  25. Parsonage M., Neuburger H. Discounting and health benefits. Health Econ. 1992 Apr;1(1):71–76. doi: 10.1002/hec.4730010110. [DOI] [PubMed] [Google Scholar]
  26. Schulman K. A., Lynn L. A., Glick H. A., Eisenberg J. M. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 May 1;114(9):798–802. doi: 10.7326/0003-4819-114-9-798. [DOI] [PubMed] [Google Scholar]
  27. Schulman K., Sulmasy D. P., Roney D. Ethics, economics, and the publication policies of major medical journals. JAMA. 1994 Jul 13;272(2):154–156. [PubMed] [Google Scholar]
  28. Smith R. Conflict of interest and the BMJ. BMJ. 1994 Jan 1;308(6920):4–5. doi: 10.1136/bmj.308.6920.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Udvarhelyi I. S., Colditz G. A., Rai A., Epstein A. M. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med. 1992 Feb 1;116(3):238–244. doi: 10.7326/0003-4819-116-3-238. [DOI] [PubMed] [Google Scholar]
  30. Wakker P., Klaassen M. P. Confidence intervals for cost/effectiveness ratios. Health Econ. 1995 Sep-Oct;4(5):373–381. doi: 10.1002/hec.4730040503. [DOI] [PubMed] [Google Scholar]
  31. Wald N. J. Couple screening for cystic fibrosis. Lancet. 1991 Nov 23;338(8778):1318–1319. doi: 10.1016/0140-6736(91)92605-2. [DOI] [PubMed] [Google Scholar]
  32. Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. doi: 10.1093/oxfordjournals.bmb.a071211. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES